Hyundai Bioscience Co., Ltd. (KOSDAQ:048410)

Hyundai Bioscience Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	63,476	3,657	1,812	2,732	9,189	19,215
Short-Term Investments	14,810	-	10,000	16,000	13,010	-
Cash & Short-Term Investments	78,286	3,657	11,812	18,732	22,199	19,215
Cash Growth	1925.74%	-69.04%	-36.94%	-15.62%	15.53%	172.36%
Accounts Receivable	166.32	247.21	446.21	1,277	7,628	11,035
Other Receivables	190.27	85.09	19.54	50.97	55.15	2,414
Receivables	356.59	332.3	465.75	1,671	8,825	17,250
Inventory	1,730	1,076	2,588	2,946	3,350	4,215
Prepaid Expenses	358.73	381.52	204.45	568.66	337.92	195
Other Current Assets	1,369	1,364	92.36	93.33	138.65	985
Total Current Assets	82,101	6,810	15,163	24,012	34,851	41,860
Property, Plant & Equipment	4,280	3,583	2,904	6,376	6,073	6,674
Long-Term Investments	21,560	22,732	1,593	1,469	4,930	4,875
Other Intangible Assets	33,170	33,170	31,170	33,175	33,664	39,395
Other Long-Term Assets	399.48	498.05	914.36	1,268	929.34	877.22
Total Assets	142,393	67,705	52,792	67,327	80,528	93,741
Accounts Payable	588.29	555.33	430.52	686.72	191.61	178.17
Accrued Expenses	196.59	137.19	141.71	141.35	123.66	143.59
Short-Term Debt	21,643	25,832	5,400	5,900	14,014	6,400
Current Portion of Long-Term Debt	-	-	-	111.08	833.32	833.36
Current Portion of Leases	474.6	440.49	114.1	196.17	354.1	369.82
Other Current Liabilities	1,186	521.41	860.43	1,957	1,744	1,652
Total Current Liabilities	24,088	27,487	6,947	8,992	17,261	9,577
Long-Term Debt	-	-	-	-	111.08	29,112
Long-Term Leases	311.88	320.53	32.43	41.7	174.69	423.22
Long-Term Deferred Tax Liabilities	-	-	-	-	1,296	2,073
Other Long-Term Liabilities	459.04	459.04	541.56	57.23	57.23	15
Total Liabilities	24,859	28,266	7,521	9,091	18,957	41,403
Common Stock	24,011	19,911	19,905	19,841	19,330	17,958
Additional Paid-In Capital	119,964	39,806	38,827	145,476	133,406	104,930
Retained Earnings	-25,880	-19,741	-12,812	-106,288	-90,481	-70,430
Treasury Stock	-4.04	-4.04	-4.04	-4.04	-4.04	-4.04
Comprehensive Income & Other	-557.01	-532.99	-645.72	-789.52	-680.57	-116.86
Shareholders' Equity	117,534	39,438	45,271	58,235	61,571	52,338
Total Liabilities & Equity	142,393	67,705	52,792	67,327	80,528	93,741
Total Debt	22,429	26,593	5,547	6,249	15,488	37,138
Net Cash (Debt)	55,856	-22,937	6,265	12,483	6,712	-17,923
Net Cash Growth	-	-	-49.81%	86.00%	-	-
Net Cash Per Share	1367.55	-576.04	157.52	317.10	181.81	-499.06
Filing Date Shares Outstanding	48.02	39.82	39.81	39.68	38.66	35.91
Total Common Shares Outstanding	48.02	39.82	39.81	39.68	38.66	35.91
Working Capital	58,013	-20,677	8,216	15,020	17,590	32,283
Book Value Per Share	2447.64	990.43	1137.24	1467.61	1592.73	1457.32
Tangible Book Value	84,364	6,269	14,101	25,061	27,906	12,943
Tangible Book Value Per Share	1756.88	157.42	354.23	631.56	721.89	360.39
Land	1,100	1,100	1,100	1,100	1,100	1,100
Buildings	3,834	3,834	3,834	5,190	5,190	5,190
Machinery	10,435	10,435	10,435	11,644	13,822	13,822
Construction In Progress	864.29	980.27	16	773.4	225	-

Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.